Pfizer-BioNTech COVID-19 vaccine
Pfizer-BioNTech COVID-19 vaccine is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
75.0%
3 of 4 finished
25.0%
1 ended early
1
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
COVID-19 Vaccine Boosters in Patients With CKD
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers
Clinical Trials (5)
Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
COVID-19 Vaccine Boosters in Patients With CKD
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
Adverse Reactions Following COVID-19 Vaccination Among Ecuadorian Healthcare Workers
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5